California to sell state-branded Narcan generic to cut costs
California has said it will start selling its own generic version of overdose reversal agent naloxone in another example of the use of government-level purchasing power to
Prime editing comes of age as FDA clears human trials
Prime Medicine has been given the go-ahead by the FDA for the first human trial of its prime editing technology, which promises to deliver one-shot therapies for a range o
BMS, J&J challenges to Medicare negotiations are thrown out
In another setback for the pharma industry, a US federal judge has rejected a bid to overturn the Medicare pricing negotiation brought by Bristol-Myers Squibb and Johnson
X4 Pharma gets first FDA okay for WHIM syndrome drug
Patients in the US with the ultra-rare disease WHIM syndrome now have their first approved treatment, after X4 Pharma’s Xolremdi was given a green light by the FDA.
Ono swoops on Deciphera in $2.4 billion takeover
Japan’s Ono Pharma has bolstered its cancer pipeline with a $2.4 billion agreement to buy Deciphera Pharma of the US and its fast-growing gastrointestinal stromal tumour (
Sales & Marketing
Digital
Market Access
Oncology
Patients
R&D
Partner Content
FT US PHARMA AND BIOTECH SUMMIT
2024 is a pivotal year for the US healthcare sector.
2nd ADC Toxicity Summit 2024
Improving Prediction & Translation of ADC Toxicities to Drive More Tolerable ADCs Successfully Into & Through Clinical Development
15th World Bispecific Summit 2024
Radically Optimize Bi, Tri & Multispecific Antibodies to Enhance Target Discovery, Mechanistic Diversity & Clinical Translation to Maximize the Therapeutic Index & Enhance Combi
9th Microbiome Movement Drug Development Summit
The Home of Accelerating Microbial-Based Drug Development
The PM Society – Giving Back
The PM Society is a not-for-profit organisation with 40 years of Giving Back.